Toxicity and biodistribution of an iodine‐131‐radiolabelled tumour necrosis‐targeting antibody in non‐tumour‐bearing domestic felines
Identifieur interne : 001705 ( Main/Exploration ); précédent : 001704; suivant : 001706Toxicity and biodistribution of an iodine‐131‐radiolabelled tumour necrosis‐targeting antibody in non‐tumour‐bearing domestic felines
Auteurs : D. M. Van Walleghen [États-Unis] ; M. H. Parseghian [États-Unis]Source :
- Veterinary and Comparative Oncology [ 1476-5810 ] ; 2006-03.
Abstract
The potential of human immunotherapeutics now revolutionizing modern cancer therapy has yet to make an impact in veterinary medicine, mainly due to the evolutionary differences between human and non‐human cell surface antigens which bar the efficacy for many antibodies targeting human antigens. Here, we explore the possible use of an iodine‐131 (I‐131)‐radiolabelled chimericTNT‐1/B antibody, Cotara, being tested in humans, which targets a highly conserved structure present in all solid tumours. The goal was to document the possible toxic side‐effects, retention, excretion and biodistribution of Cotara in non‐tumour‐bearing felines. The study was conducted with six lab animal domestic shorthaired felines. Two felines were randomly placed into three dose groups: 1.5, 2.0, and 3.0 mCi kg−1 (0.68, 0.9 and 1.36 mCi lb−1); these doses were administered by a single IV injection. Thyroid blockade with potassium iodide (KI) was administered orally once daily. Over the 90‐day study, haematologic test results, serum chemistry, thyroid function, food intake and morbidity were recorded. Drug distribution was ascertained through nuclear scintigraphy. Four of the six subjects had decreased appetite (Grade 1) that started on day 4 and then resolved by day 10. Two subjects exhibited intermittent days of anorexia (Grade 2) from day 5 to day 13. Both subjects with Grade 2 anorexia were sacrificed and necropsied once each exhibited two consecutive days of signs. Vomiting (Grade 2) occurred in 3 subjects from day 4 to day 13. Three subjects had moderate regenerative anaemia (Grade 2), whereas two developed leucocytosis. Overall, a single intravenous dose of Cotara resulted in moderate toxicity, with subjects exhibiting transitory signs of anorexia and vomiting without laboratory evidence of organ pathology. Each subject received a once daily oral dose of KI (33 mg) that was found to be safe and effective in the prevention of radiation damage to the thyroid gland over the study period. With a moderate toxicity profile, Cotara may hold unique promise by delivering I‐131 directly into solid tumours of various types in felines.
Url:
DOI: 10.1111/j.1476-5810.2006.00086.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000767
- to stream Istex, to step Curation: 000734
- to stream Istex, to step Checkpoint: 000214
- to stream Main, to step Merge: 001711
- to stream Main, to step Curation: 001705
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Toxicity and biodistribution of an iodine‐131‐radiolabelled tumour necrosis‐targeting antibody in non‐tumour‐bearing domestic felines</title><author><name sortKey="Van Walleghen, D M" sort="Van Walleghen, D M" uniqKey="Van Walleghen D" first="D. M." last="Van Walleghen">D. M. Van Walleghen</name></author><author><name sortKey="Parseghian, M H" sort="Parseghian, M H" uniqKey="Parseghian M" first="M. H." last="Parseghian">M. H. Parseghian</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:5757E24E817364F5AB8DE6FAAFB2595627DB1FDE</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1476-5810.2006.00086.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-CFXSNL3G-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000767</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000767</idno><idno type="wicri:Area/Istex/Curation">000734</idno><idno type="wicri:Area/Istex/Checkpoint">000214</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000214</idno><idno type="wicri:doubleKey">1476-5810:2006:Van Walleghen D:toxicity:and:biodistribution</idno><idno type="wicri:Area/Main/Merge">001711</idno><idno type="wicri:Area/Main/Curation">001705</idno><idno type="wicri:Area/Main/Exploration">001705</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Toxicity and biodistribution of an iodine‐131‐radiolabelled tumour necrosis‐targeting antibody in non‐tumour‐bearing domestic felines</title><author><name sortKey="Van Walleghen, D M" sort="Van Walleghen, D M" uniqKey="Van Walleghen D" first="D. M." last="Van Walleghen">D. M. Van Walleghen</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Jersey‐Calhoun Veterinary Hospital, Jerseyville, IL</wicri:regionArea><placeName><region type="state">Illinois</region></placeName></affiliation><affiliation></affiliation></author><author><name sortKey="Parseghian, M H" sort="Parseghian, M H" uniqKey="Parseghian M" first="M. H." last="Parseghian">M. H. Parseghian</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Peregrine Pharmaceuticals Inc., Tustin, CA</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Veterinary and Comparative Oncology</title><title level="j" type="alt">VETERINARY COMPARATIVE ONCOLOGY</title><idno type="ISSN">1476-5810</idno><idno type="eISSN">1476-5829</idno><imprint><biblScope unit="vol">4</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="9">9</biblScope><biblScope unit="page" to="20">20</biblScope><biblScope unit="page-count">12</biblScope><publisher>Blackwell Publishing Ltd</publisher><pubPlace>Oxford, UK; Malden, USA</pubPlace><date type="published" when="2006-03">2006-03</date></imprint><idno type="ISSN">1476-5810</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1476-5810</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The potential of human immunotherapeutics now revolutionizing modern cancer therapy has yet to make an impact in veterinary medicine, mainly due to the evolutionary differences between human and non‐human cell surface antigens which bar the efficacy for many antibodies targeting human antigens. Here, we explore the possible use of an iodine‐131 (I‐131)‐radiolabelled chimericTNT‐1/B antibody, Cotara, being tested in humans, which targets a highly conserved structure present in all solid tumours. The goal was to document the possible toxic side‐effects, retention, excretion and biodistribution of Cotara in non‐tumour‐bearing felines. The study was conducted with six lab animal domestic shorthaired felines. Two felines were randomly placed into three dose groups: 1.5, 2.0, and 3.0 mCi kg−1 (0.68, 0.9 and 1.36 mCi lb−1); these doses were administered by a single IV injection. Thyroid blockade with potassium iodide (KI) was administered orally once daily. Over the 90‐day study, haematologic test results, serum chemistry, thyroid function, food intake and morbidity were recorded. Drug distribution was ascertained through nuclear scintigraphy. Four of the six subjects had decreased appetite (Grade 1) that started on day 4 and then resolved by day 10. Two subjects exhibited intermittent days of anorexia (Grade 2) from day 5 to day 13. Both subjects with Grade 2 anorexia were sacrificed and necropsied once each exhibited two consecutive days of signs. Vomiting (Grade 2) occurred in 3 subjects from day 4 to day 13. Three subjects had moderate regenerative anaemia (Grade 2), whereas two developed leucocytosis. Overall, a single intravenous dose of Cotara resulted in moderate toxicity, with subjects exhibiting transitory signs of anorexia and vomiting without laboratory evidence of organ pathology. Each subject received a once daily oral dose of KI (33 mg) that was found to be safe and effective in the prevention of radiation damage to the thyroid gland over the study period. With a moderate toxicity profile, Cotara may hold unique promise by delivering I‐131 directly into solid tumours of various types in felines.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Californie</li><li>Illinois</li></region></list><tree><country name="États-Unis"><region name="Illinois"><name sortKey="Van Walleghen, D M" sort="Van Walleghen, D M" uniqKey="Van Walleghen D" first="D. M." last="Van Walleghen">D. M. Van Walleghen</name></region><name sortKey="Parseghian, M H" sort="Parseghian, M H" uniqKey="Parseghian M" first="M. H." last="Parseghian">M. H. Parseghian</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001705 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001705 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:5757E24E817364F5AB8DE6FAAFB2595627DB1FDE
|texte= Toxicity and biodistribution of an iodine‐131‐radiolabelled tumour necrosis‐targeting antibody in non‐tumour‐bearing domestic felines
}}
| This area was generated with Dilib version V0.6.33. |  |